Robert Goldman

机构：Sumitomo Dainippon Pharma (United States)

发表论文 133 篇 · 总被引 7061 次 · h-index 39

代表论文

• A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia (2020 · New England Journal of Medicine · 被引 292)
• Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study (2021 · Schizophrenia · 被引 85)
• Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, fixed-dose clinical trial (2020 · CNS Spectrums · 被引 42)
• Efficacy and Safety of Dasotraline in Adults With Binge-Eating Disorder (2020 · The Journal of Clinical Psychiatry · 被引 31)
• Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia (2022 · European Psychiatry · 被引 14)
• Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies (2021 · European Psychiatry · 被引 14)